Sign in
Explore the registryTrack Lebrikizumab's trials

ADorable-1

A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

LebrikizumabOngoingActive not recruitingPhase 3Open NCT05559359 on ClinicalTrials.gov ↗

Population

Loading…

Intervention

Loading…

Comparator

Loading…

Loading…